Clinical evaluation of plasma free phenytoin measurement and factors influencing its protein binding

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 2, 2006, Pages 77-84

  Iwamoto, Takuya ^a   Kagawa, Yoshiyuki ^a   Naito, Yutaka ^a   Kuzuhara, Shigeki ^a   Okuda, Masahiro ^a  

^a MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Free phenytoin; Phenytoin; Protein binding; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; PHENYTOIN;

ADOLESCENT; ADULT; AGED; AGING; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG MONITORING; DRUG PROTEIN BINDING; FEMALE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; CREATININE; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; PROTEIN BINDING; RETROSPECTIVE STUDIES; SEIZURES; SERUM ALBUMIN;

EID: 33645276828     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.486     Document Type: Article

References (20)

1. Nuwer MR, Browne TR, Dodson WE, et al. Generic substitutions for antiepileptic drugs. Neurology 1990; 40: 1647-1651.
2. Kutt H, McDowell F. Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients. JAMA 1968; 203: 969-972.
3. Lund M, Jorgensen RS, Kuehl V. Serum diphenylhydantoin (phenytoin) in ambulant patients with epilepsy. Epilepsia 1964; 5: 51-58.
4. Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med 1999; 123: 822-823.
5. DeMonaco HJ, Lawless LM. Variability of phenytoin protein binding in epileptic patients. Arch Neurol 1983; 40: 481-483.
6. Peterson GM, Khoo BH, von Witt RJ. Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit 1991; 13: 415-419.
7. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002; 24: 379-385.
8. Theodore WH, Yu L, Price B, et al. The clinical value of free phenytoin levels. Ann Neurol 1985; 18: 90-93.
9. May TW, Rambeck B, Jurges U, Blankenhorn V, Jurgens U. Comparison of total and free phenytoin serum concentrations measured by high-performance liquid chromatography and standard TDx assay: implications for the prediction of free phenytoin serum concentrations. Ther Drug Monit 1998; 20: 619-623.
10. Lenn NJ, Robertson M. Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy. Neurology 1992; 42: 988-990.
11. Burt M, Anderson DC, Kloss J, Apple FS. Evidence-based implementation of free phenytoin therapeutic drug monitoring. Clin Chem 2000; 46: 1132-1135.
12. Fedler C, Stewart MJ. Plasma total phenytoin: a possibly misleading test in developing countries. Ther Drug Monit 1999; 21: 155-160.
13. Levine M, Chang T. Therapeutic drug monitoring of phenytoin. Rationale and current status. Clin Pharmacokinet 1990; 19: 341-358.
14. Kilpatrick CJ, Wanwimolruk S, Wing LM. Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmacol 1984; 17: 539-546.
15. Dasgupta A, Dennen DA, Dean R, McLawhon RW. Prediction of free phenytoin levels based on [total phenytoin]/[albumin] ratios. Potential errors with hypoalbuminemia. Am J Clin Pathol 1991; 95: 253-256.
16. Liponi DF, Winter ME, Tozer TN. Renal function and therapeutic concentrations of phenytoin. Neurology 1984; 34: 395-397.
17. Mabuchi H, Nakahashi H. A major inhibitor of phenytoin binding to serum protein in uremia. Nephron 1988; 48: 310-314.
18. Bender AD, Post A, Meier JP, Higson JE, Reichard G Jr. Plasma protein binding of drugs as a function of age in adult human subjects. J Pharm Sci 1975; 64: 1711-1713.
19. Patterson M, Heazelwood R, Smithurst B, Eadie MJ. Plasma protein binding of phenytoin in the aged: in vivo studies. Br J Clin Pharmacol 1982; 13: 423-425.
20. Baird-Lambert J, Manglick MP, Wall M, Buchanan N. Identifying patients who might benefit from free phenytoin monitoring. Ther Drug Monit 1987; 9: 134-138.